IFPMA Covid-19 Günlük Bülteni – 15 Mayıs

15.05.2020

Top news:

  • WHO and Costa Rica’s president announced that the official call to action to join the voluntary patent pool for COVID-19 medical tools will be launched on 29 May.
  • India asks G20 nations to ensure access to essential medicines, treatments and vaccines at affordable prices.
  • Sanofi announced there will be no particular advance given to any country when it comes to the distribution of its vaccine.
  • Takeda may aim to enter the COVID-19 vaccine race but warns industry of the difficulties of developing and manufacturing such products.
  • Two policy briefs by the ILO highlight how COVID-19 has exposed gaps in social protection coverage in LMICs which could compromise recovery plans, increase global poverty and affect global preparedness to cope with similar crises.
  • Later tonight, WHO will release a scientific brief on multisystem inflammatory syndrome in children which could be linked to COVID-19.

WORLD HEALTH ASSEMBLY

IP, PRICING & ACCESS

SUPPLY & MANUFACTURING

GLOBAL RESPONSE

GLOBAL ECONOMIC IMPACT

GLOBAL HEALTH/ SOCIAL IMPACT

TREATMENT & VACCINE DEVELOPMENT

IFPMA members

Others

  • The Guardian: UK spent £20m buying up stocks of HIV and malaria drugs.  The UK government has spent nearly £20 and has entered 16 contracts for chloroquine, hydroxychloroquine, and chloroquine phosphate used for malaria and other diseases and placed major orders for lopinavir-ritonavir.
  • BBC News: Macaque monkey trial offers hope. A trial took place in the US, involving researchers from the US government’s National Institutes of Health (NIH) and from the University of Oxford found that a vaccine against coronavirus appears to have provided protection against the disease COVID-19 in six rhesus macaque monkeys.
  • Economic Times: Russia inches closer to create drug to treat COVID-19. Russia’s sovereign wealth fund, and top pharmacy group from Russia ChemRar Group announced first and positive interim results of the multicenter randomized open comparative clinical trial of the drug Favipiravir on patients hospitalized with COVID-19.
  • The Motley Fool: Is Inovio Gaining Ground in the Coronavirus Vaccine Race? Inovio has recently completed enrolment in a phase one trial and it is a step behind Moderna on the coronavirus vaccine timeline.
  • Bloomberg: Tobacco-Based Coronavirus Vaccine Poised for Human Tests.  An experimental COVID-19 vaccine developed by cigarette maker British American Tobacco Plc is poised to begin testing in humans. Pre-clinical tests of the vaccine showed a positive immune response.
  • The Hindu: No link between BCG vaccination, coronavirus in Israel. Researchers in Israel did not find any key difference in proportion of positive test results in vaccinated, unvaccinated groups of the BCG vaccine.

New Partnerships

DONATIONS

DIAGNOSTICS

CLINICAL TRIALS

  • Politico (Paywall): EMA warns about too-small studies for COVID-19 medicines. The agency called on countries to cooperate in order to conduct the kind of large-scale trials needed to verify the efficacy of potential treatments and vaccines against COVID-19.
  • Fortune: Will COVID-19 change how Big Pharma does clinical trials? A randomized, double-blind, placebo-controlled trial has long been considered the gold standard in medicine, but it’s not easy to pull off in the middle of a pandemic and this may change how clinical trials are designed moving forward.

EPIDEMIOLOGY

CORONAVIRUS & AFRICA

GEOPOLITICS

  • FT: Trump threatens to cut off relations with China. Donald Trump has warned that he could “cut off the whole relationship” with China, in the latest escalation of US tensions with Beijing as he increasingly blames China for the global spread of the coronavirus.

WHO – COVID-19 UPDATE, 15 May

Statement by Dr Tedros during today’s media briefing here.

  • We are seeing some good examples where companies are coming out with solidarity approaches – from open licensing and support, to tech transfer via the new Tech Access Partnership, to commitments not to increase prices in times of shortages.
  • WHO recognizes the wide-ranging efforts and initiatives aimed at incentivizing innovation while also ensuring access for all. These will be important topics next week at the World Health Assembly.
  • Yesterday, WHO released a policy brief on gender and COVID-19, which encourages countries to incorporate a gender focus into their responses.
  • This evening, WHO will release a Scientific Brief on Multisystem Inflammatory Syndrome in Children.
  • In the past weeks, reports from Europe and North America have described a small number of children being admitted to intensive care units with a multisystem inflammatory condition with some features similar to Kawasaki’s disease and toxic shock syndrome.
  • Initial reports hypothesise that this syndrome may be related to COVID-19.

Statement by Costa Rica’s President Alvarado during WHO’s media briefing:

  • Costa Rica proposed to create a global repository of IP with data, knowledge, tech, and design of COVID-19
  • The idea is to make this repository with advancement and innovation available at the lowest cost to ensure it can be available to everyone
  • This would be done on a voluntary basis as we need solidarity more than ever.
  • Over the past two months, so much knowledge and science has been developed and we need to pool this together.
  • Understanding that this pandemic affects all countries the same regardless if you have resources
  • This is a call to action for creating a repository and global pool for rights to make the development more accessible and available for all so the world together
  • Call is for member states, private sector, academic, research institution and corporation institutions on a voluntary basis
  • All of this should be a global public good to protect the world from this pandemic
  • The official call to action will be launched on May 29th and they are still waiting for more member states to join
  • Only with multilateralism can we overcome COVID-19, not with nationalism and selfishness
  • This is a great opportunity to show the best of humanity

WHO: DRAFT landscape of COVID-19 candidate vaccines – 15 May 2020.

  • 8 candidate vaccines in clinical evaluation

110 candidate vaccines in preclinical evaluation